NuTide:121 will compare NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients with Advanced Biliary Tract Cancer.

The study opened to recruitment in December 2019 and will enrol up to 828 patients globally. There will be a number of UK sites be participating.

(The NUC-1031 Plus Cisplatin combination was developed through the UK ABC-08 study)

NuTide:121 is open and recruiting at the following sites:

Principal Investigator Site
Palmer, Daniel The Clatterbridge Cancer Centre
Valle, Juan The Christie
Ross, Paul Guy’s Hospital
Braconi, Chiara Beatson West of Scotland Cancer Centre
Christie, Alan Western General Hospital
Rees, Charlotte Southampton General Hospital – due to open at this site during 2020

Tel: +44 (0)131 357 1111

Back to previous page